title: Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men.
abstract: Surveys indicate that one form of acceptable male hormonal contraception would consist of injections given at 2- to 3-month intervals. This report describes a study of depot medroxyprogesterone acetate (DMPA) and testosterone undecanoate (TU) injected at 8-wk intervals for suppression of spermatogenesis in healthy Chinese men. After screening, 30 healthy volunteers were enrolled and randomly assigned to one of three dose groups (n = 10/group): 1000 mg TU (group A); 1000 mg TU plus 150 mg DMPA (group B); 1000 mg TU plus 300 mg DMPA (group C). All doses were given as im injections at 8-wk intervals. The study consisted of an 8-wk control (baseline) period, a 24-wk treatment period, and a 24-wk recovery period. Consistent azoospermia or severe oligozoospermia was achieved and maintained in all volunteers during the treatment period, except for two men in the TU-alone group who experienced a rebound in sperm concentrations. An 8-wk regimen of TU plus DMPA at both tested combination doses effectively suppressed spermatogenesis to azoospermia in Chinese men. All volunteers tolerated the injections; no serious adverse effects were reported. The lower-dose combination is recommended for further testing in an expanded clinical trial or contraceptive efficacy study.
authors.affiliation: National Research Institute for Family Planning, Beijing 100081, China. ygu90@hotmail.com
authors.forename: Yi-Qun
authors.initials: YQ
authors.lastname: Gu
authors.forename: Jian-Sun
authors.initials: JS
authors.lastname: Tong
authors.forename: Ding-Zhi
authors.initials: DZ
authors.lastname: Ma
authors.forename: Xing-Hai
authors.initials: XH
authors.lastname: Wang
authors.forename: Dong
authors.initials: D
authors.lastname: Yuan
authors.forename: Wen-Hao
authors.initials: WH
authors.lastname: Tang
authors.forename: William J
authors.initials: WJ
authors.lastname: Bremner
mesh_terms: D000328:Adult; D044466:Asian People; D003272:Contraceptive Agents, Male / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D012739:Gonadal Steroid Hormones / Q000097:blood; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007273:Injections, Intramuscular; D008055:Lipids / Q000097:blood; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D013076:Sperm Count; D013091:Spermatogenesis / Q000187:drug effects*; D013739:Testosterone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D003272:Contraceptive Agents, Male; D003692:Delayed-Action Preparations; D012739:Gonadal Steroid Hormones; D006454:Hemoglobins; D008055:Lipids; D013739:Testosterone; D017258:Medroxyprogesterone Acetate; C010792:testosterone undecanoate